Sean Wuxiong Cao

Managing Director

Billy Cho

Senior Managing Director of PE and Co-Head

Ma Ke

Managing Director

3 past transactions

Axbio

Series B in 2022
Axbio manufactures next-generation gene sequencing and diagnostic high-end equipment and providing complete industrial solutions.

InxMed

Series B in 2022
InxMed is a clinical-stage biotech company focusing on developing "Best-in-Disease Combination" medicines to bring novel treatment options for patients. Our innovations are inspired by patients and driven by an in-depth understanding of disease biology and pharmacology. InxMed is committed to building a translational platform equipped with global-level top-notch know-how and efficient execution capabilities.

ENSEM Therapeutics

Series A in 2022
ENSEM Therapeutics is a pioneering drug discovery and development company that leverages its unique Kinetic EnsembleTM platform to develop innovative small-molecule precision medicines for oncology, with potential expansion into genetic disorders and other disease areas.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.